CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma

Anaplastic lymphoma kinase (ALK) gene rearrangements are oncogenic drivers in a small subset of patients with non-small-cell lung cancer (NSCLC). The ALK inhibitors are highly effective in NSCLC patients harboring ALK rearrangements; however, most patients acquire resistance to the therapy following...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Rong, Wang, Yisong, Voeller, Donna, Gower, Arjan, Kim, In-Kyu, Zhang, Yu-Wen, Giaccone, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045389/
https://www.ncbi.nlm.nih.gov/pubmed/27078848
http://dx.doi.org/10.18632/oncotarget.8638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045389/
https://www.ncbi.nlm.nih.gov/pubmed/27078848
http://dx.doi.org/10.18632/oncotarget.8638

Ejemplares similares